Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Almirall ( (ES:ALM) ) has shared an announcement.
Almirall has announced details of a scrip dividend approved by its Ordinary General Shareholders’ Meeting held on 8 May 2026, opting to implement the payout via a capital increase charged to reserves from undistributed profits. The company has prepared an information document in line with EU regulatory requirements, signalling continued use of shareholder-friendly remuneration tools while preserving cash, a move that may appeal to income-seeking investors and support balance-sheet flexibility.
The scrip dividend structure allows shareholders to receive new shares instead of cash, effectively reinvesting retained earnings into equity and slightly diluting existing holdings. By aligning the capital increase with European prospectus regulations, Almirall underscores its commitment to regulatory compliance and transparent communication with the market, which may help sustain investor confidence ahead of future capital and dividend decisions.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a pharmaceutical company focused on developing and marketing prescription medicines, with a particular emphasis on dermatology and other specialty therapeutic areas. The company operates globally, targeting both primary care and specialist markets through a portfolio of innovative and established treatments.
Average Trading Volume: 149,849
Technical Sentiment Signal: Buy
Current Market Cap: €2.57B
For a thorough assessment of ALM stock, go to TipRanks’ Stock Analysis page.